Company Product Description Indication Status
Algernon Pharmaceuticals Inc., of Vancouver, British Columbia NP-120 (ifenprodil) NDMA receptor glutamate receptor antagonist specifically targeting NMDA-type subunit 2B  Prevention of acute lung injury and acute respiratory distress syndrome associated with COVID-19 Requested pre-IND meeting with FDA, asking for direction regarding use of injectable and slow-release formulation as well as currently available drug supply for a U.S. clinical trial on an emergency basis; filing also includes clarification of expanded access pathway
GW Pharmaceuticals plc, of London Epidyolex  Cannabidiol oral solution Seizures associated with tuberous sclerosis complex Submitted type II variation application to EMA; if approved, it will be the third licensed indication for the drug in Europe

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments